Pharvaris (PHVS) Net Income (2020 - 2026)
Pharvaris' (PHVS) quarterly Net Income came in at -$45.3 million in Q1 2026, up 5.93% YoY from -$42.7 million in Q1 2025, and up 10.45% on a QoQ basis from -$50.5 million in Q4 2025.
Analysis
Pharvaris (PHVS) Net Income (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Net Income data on file, last reported at -$45.3 million in Q1 2026.
- Quarterly Net Income rose 5.93% year-over-year to -$45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$190.7 million (down 19.33% YoY) and the FY2025 annual result came in at -$194.0 million, down 37.29% from the prior year.
- Net Income improved to -$45.3 million in Q1 2026, from -$50.5 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$7.6 million in Q2 2022 to a low of -$51.0 million in Q2 2025.
- A 5-year average of -$33.6 million and a median of -$34.5 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income surged 58.38% — and 2023, when it sank 210.34%.
- Tracing PHVS's Net Income over 5 years: stood at -$41.5 million in 2022, then grew by 10.56% to -$37.1 million in 2023, then gained by 6.95% to -$34.5 million in 2024, then slumped by 46.49% to -$50.5 million in 2025, then gained by 10.45% to -$45.3 million in 2026.
- The last three Net Income figures came in at -$45.3 million (Q1 2026), -$50.5 million (Q4 2025), and -$43.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | -54.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54.21 Mn |
| Mar 31, 2026 | -45.25 Mn |
| Dec 31, 2025 | -50.53 Mn |
| Sep 30, 2025 | -43.84 Mn |
| Jun 30, 2025 | -51.02 Mn |
| Mar 31, 2025 | -48.11 Mn |
| Dec 31, 2024 | -34.50 Mn |
| Sep 30, 2024 | -45.30 Mn |
| Jun 30, 2024 | -31.86 Mn |
| Mar 31, 2024 | -29.82 Mn |
| Dec 31, 2023 | -33.63 Mn |
| Sep 30, 2023 | -25.37 Mn |
| Jun 30, 2023 | -23,640.02 Bn |
| Mar 31, 2023 | -24.16 Mn |
| Dec 31, 2022 | -39.37 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -7,617.57 Bn |
| Mar 31, 2022 | -17.90 Mn |
| Dec 31, 2021 | -14.16 Mn |
| Sep 30, 2021 | -10.62 Mn |